Bisphosphonates and breast cancer prevention

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 144-150

  Chlebowski, Rowan T ^a   Col, Nananda ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant treatment; Anti cancer; Bisphosphonates; Early breast cancer; Prevention; Zoledronic acid

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DENOSUMAB; FLUOROURACIL; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; DISEASE FREE SURVIVAL; FEMUR FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOLYSIS;

EID: 84856252046     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012799014913     Document Type: Article

References (57)

1. National Osteoporosis Foundation, Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation: Washington, DC. http://www.nof.org/sites/default/files/pdfs/NOS_CinicianGuide2009_v7.pdf. (Accessed June 8, 2011), 2010.
2. Elomaa, I.; Blomqvist, C.; Porkka, L.; Lamberg-Allardt, C.; Borgstrom, G. H., Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone, 1987, 8(suppl 1), S53-S56.
3. Brufsky, A.; Bundred, N.; Coleman, R.; Lambert-Falls, R.; Mena, R.; Hadji, P.; Jin, L.; Schenk, N.; Ericson, S.; Perez, E. A., Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist, 2008, 13(5), 503-514.
4. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Postlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rucklinger, E.; Greil, R.; Marth, C., Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med., 2009, 360(7), 679-691.
5. Morgan, G. J.; Davies, F. E.; Gregory, W. M.; Cocks, K.; Bell, S. E.; Szubert, A. J.; Navarro-Coy, N.; Drayson, M. T.; Owen, R. G.; Feyler, S.; Ashcroft, A. J.; Ross, F.; Byrne, J.; Roddie, H.; Rudin, C.; Cook, G.; Jackson, G. H.; Child, J. A., First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 2010, 376(9757), 1989-1999.
6. Winter, M. C.; Holen, I.; Coleman, R. E., Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev., 2008, 34(5), 453-475.
7. Green, J.; Lipton, A., Anticancer properties of zoledronic acid. Cancer Invest., 2010, 28(9), 944-957.
8. Bedard, P. L.; Body, J. J.; Piccart-Gebhart, M. J., Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. J. Clin. Oncol., 2009, 27(25), 4043-4046.
9. Hashimoto, K.; Morishige, K.; Sawada, K.; Tahara, M.; Shimizu, S.; Ogata, S.; Sakata, M.; Tasaka, K.; Kimura, T., Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun., 2007, 354(2), 478-484.
10. Santini, D.; Vincenzi, B.; Galluzzo, S.; Battistoni, F.; Rocci, L.; Venditti, O.; Schiavon, G.; Angeletti, S.; Uzzalli, F.; Caraglia, M.; Dicuonzo, G.; Tonini, G., Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res., 2007, 13(15 Pt 1), 4482-4486.
11. Coleman, R. E., Risks and benefits of bisphosphonates. Br. J. Cancer, 2008, 98(11), 1736-1740.
12. Hadji, P.; Body, J. J.; Aapro, M. S.; Brufsky, A.; Coleman, R. E.; Guise, T.; Lipton, A.; Tubiana-Hulin, M., Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol., 2008, 19(8), 1407-1416.
13. Hillner, B. E.; Ingle, J. N.; Chlebowski, R. T.; Gralow, J.; Yee, G. C.; Janjan, N. A.; Cauley, J. A.; Blumenstein, B. A.; Albain, K. S.; Lipton, A.; Brown, S., American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol., 2003, 21(21), 4042-4057.
14. Fuleihan, G. E.-H.; Salamoun, M.; Mourad, Y. A.; Chehal, A.; Salem, Z.; Mahfoud, Z.; Shamseddine, A., Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab., 2005, 90(6), 3209-3214.
15. Chlebowski, R.; Cuzick, J.; Amakye, D.; Bauerfeind, I.; Buzdar, A.; Chia, S.; Cutuli, B.; Linforth, R.; Maass, N.; Noguchi, S.; Robidoux, A.; Verma, S.; Hadji, P., Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast, 2009, 18(suppl 2), S1-S11.
16. Body, J. J.; Diel, I. J.; Lichinitzer, M.; Lazarev, A.; Pecherstorfer, M.; Bell, R.; Tripathy, D.; Bergstrom, B., Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebocontrolled phase III studies. Br. J. Cancer, 2004, 90(6), 1133-1137.
17. Lester, J. E.; Dodwell, D.; Purohit, O. P.; Gutcher, S. A.; Ellis, S. P.; Thorpe, R.; Horsman, J. M.; Brown, J. E.; Hannon, R. A.; Coleman, R. E., Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res., 2008, 14(19), 6336-6342.
18. Markopoulos, C.; Tzoracoleftherakis, E.; Polychronis, A.; Venizelos, B.; Dafni, U.; Xepapadakis, G.; Papadiamantis, J.; Zobolas, V.; Misitzis, J.; Kalogerakos, K.; Sarantopoulou, A.; Siasos, N.; Koukouras, D.; Antonopoulou, Z.; Lazarou, S.; Gogas, H., Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res., 2010, 12(2), R24.
19. Van Poznak, C.; Hannon, R. A.; Mackey, J. R.; Campone, M.; Apffelstaedt, J. P.; Clack, G.; Barlow, D.; Makris, A.; Eastell, R., Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J. Clin. Oncol., 2010, 28(6), 967-975.
20. Brufsky, A. M.; Bosserman, L. D.; Caradonna, R. R.; Haley, B. B.; Jones, C. M.; Moore, H. C.; Jin, L.; Warsi, G. M.; Ericson, S. G.; Perez, E. A., Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer, 2009, 9(2), 77-85.
21. Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Kainberger, F.; Kassmann, H.; Piswanger-Solkner, J. C.; Seifert, M.; Ploner, F.; Menzel, C.; Dubsky, P.; Fitzal, F.; Bjelic-Radisic, V.; Steger, G.; Greil, R.; Marth, C.; Kubista, E.; Samonigg, H.; Wohlmuth, P.; Mittlbock, M.; Jakesz, R., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol., 2008, 9(9), 840-849.
22. Hines, S. L.; Sloan, J. A.; Atherton, P. J.; Perez, E. A.; Dakhil, S. R.; Johnson, D. B.; Reddy, P. S.; Dalton, R. J.; Mattar, B. I.; Loprinzi, C. L., Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast, 2010, 19(2), 92-96.
23. Ellis, G. K.; Bone, H. G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S., Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin. Oncol., 2008, 26(30), 4875-4882.
24. Diel, I. J.; Solomayer, E. F.; Costa, S. D.; Gollan, C.; Goerner, R.; Wallwiener, D.; Kaufmann, M.; Bastert, G., Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med., 1998, 339(6), 357-363.
25. Diel, I. J.; Jaschke, A.; Solomayer, E. F.; Gollan, C.; Bastert, G.; Sohn, C.; Schuetz, F., Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol., 2008, 19(12), 2007-2011.
26. Saarto, T.; Vehmanen, L.; Virkkunen, P.; Blomqvist, C., Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol., 2004, 43(7), 650-656.
27. Powles, T.; Paterson, S.; Kanis, J. A.; McCloskey, E.; Ashley, S.; Tidy, A.; Rosenqvist, K.; Smith, I.; Ottestad, L.; Legault, S.; Pajunen, M.; Nevantaus, A.; Mannisto, E.; Suovuori, A.; Atula, S.; Nevalainen, J.; Pylkkanen, L., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol., 2002, 20(15), 3219-3224.
28. Powles, T.; Paterson, A.; McCloskey, E.; Schein, P.; Scheffler, B.; Tidy, A.; Ashley, S.; Smith, I.; Ottestad, L.; Kanis, J., Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res., 2006, 8(2), R13.
29. Mamounas, E. P., NSABP breast cancer clinical trials: recent results and future directions. Clin. Med. Res., 2003, 1(4), 309-326.
30. Aapro, M., Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZOFAST program. Breast, 2006, 15(suppl 1), S30-S40.
31. Eidtmann, H.; de Boer, R.; Bundred, N.; Llombart-Cussac, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Miller, J.; Schenk, N.; Coleman, R., Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36- month results of the ZO-FAST study. Ann. Oncol., 2010, 21(11), 2188-2194.
32. Schenk, N.; Llombart, A.; Frassoladti, A.; Neven, P.; Jerusalem, G.; Deleu, I.; Mebis, J.; Maerevoet, M.; Miller, J.; Dias, R., The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Presented at: ECCO 14, the European Cancer Conference; September 23-27, 2007; Barcelona, Spain. Abstract 2008.
33. Coleman, R.; Bundred, N.; de Boer, R.; Llombart, A.; Campbell, I.; Neven, P.; Barrios, C.; Dias, R.; Miller, J.; Brufsky, A., Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 4082.
34. Mauri, D.; Valachis, A.; Polyzos, N. P.; Tsali, L.; Mavroudis, D.; Georgoulias, V.; Casazza, G., Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J. Natl. Compr. Canc. Netw., 2010, 8(3), 279-286.
35. Tevaarwerk, A.; Stewart, J. A.; Love, R.; Binkley, N. C.; Black, S.; Eickhoff, J.; Mulkerin, D. L., Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer J. Clin. Oncol., 2007, 25(18 suppl), 711s. Abstract 19558.
36. Coleman, R. E.; Thorpe, H. C.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston, S. J.; Grieve, R. J.; Barrett-Lee, P. J.; Ritchie, D.; Davies, C.; Bell, R., Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Oral presentation at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract S4-5.
37. Coleman, R. E.; Winter, M. C.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M. M.; Gil, M.; Ritchie, D.; Passos-Coelho, J. L.; Wheatley, D.; Burkinshaw, R.; Marshall, S. J.; Thorpe, H., The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer, 2010, 102(7), 1099-1105.
38. Aft, R.; Naughton, M.; Trinkaus, K.; Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Zhai, J.; Kuo, S.; Shannon, W.; Diemer, K.; Herrmann, V.; Dietz, J.; Ali, A.; Ellis, M.; Weiss, P.; Eberlein, T.; Ma, C.; Fracasso, P. M.; Zoberi, I.; Taylor, M.; Gillanders, W.; Pluard, T.; Mortimer, J.; Weilbaecher, K., Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol., 2010, 11(5), 421-428.
39. Greenberg, S.; Park, J. W.; Melisko, M. E.; Goga, A.; Moasser, M. M.; Anderson, M.; Scott, J. H.; Petrillo, L. A.; Moore, D. H.; Rugo, H. S., Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with earlystage breast cancer (ESBC): updated results. J. Clin. Oncol., 2010, 28(15 suppl), 114s. Abstract 1002.
40. Rack, B.; Schindlbeck, C.; Strobl, B.; Sommer, H.; Friese, K.; Janni, W., [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study]. Dtsch. Med. Wochenschr., 2008, 133(7), 285-289.
41. DerSimonian, R.; Laird, N., Meta-analysis in clinical trials. Control Clin. Trials, 1986, 7(3), 177-188.
42. Gnant, M.; Mlineritsch, B.; Stoeger, H.; Luschin-Ebengreuth, G.; Heck, D.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Pristauz, G.; Bauernhofer, T.; Eidtmann, H.; Eiermann, W.; Steger, G.; Kwasny, W.; Dubsky, P.; Hochreiner, G.; Forsthuber, E. P.; Fesl, C.; Greil, R., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol., 2011, 12(7), 631-641.
43. Cauley, J. A.; Lucas, F. L.; Kuller, L. H.; Vogt, M. T.; Browner, W. S.; Cummings, S. R., Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA, 1996, 276(17), 1404-1408.
44. Chen, Z.; Arendell, L.; Aickin, M.; Cauley, J.; Lewis, C. E.; Chlebowski, R., Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer, 2008, 113(5), 907-915.
45. Chlebowski, R. T.; Chen, Z.; Cauley, J. A.; Anderson, G.; Rodabough, R. J.; McTiernan, A.; Lane, D. S.; Manson, J. E.; Snetselaar, L.; Yasmeen, S.; O'Sullivan, M. J.; Safford, M.; Hendrix, S. L.; Wallace, R. B., Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J. Clin. Oncol., 2010, 28(22), 3582-3590.
46. Robbins, J.; Aragaki, A. K.; Kooperberg, C.; Watts, N.; Wactawski-Wende, J.; Jackson, R. D.; LeBoff, M. S.; Lewis, C. E.; Chen, Z.; Stefanick, M. L.; Cauley, J., Factors associated with 5- year risk of hip fracture in postmenopausal women. JAMA, 2007, 298(20), 2389-2398.
47. Newcomb, P. A.; Trentham-Dietz, A.; Hampton, J. M., Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer, 2010, 102(5), 799-802.
48. Rennert, G.; Pinchev, M.; Rennert, H. S., Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol., 2010, 28(22), 3577-3581.
49. Vestergaard, P.; Fischer, L.; Mele, M.; Mosekilde, L.; Christiansen, P., Use of bisphosphonates and risk of breast cancer. Calcif. Tissue Int., 2011, 88(4), 255-262.
50. Winter, M. C.; Thorpe, H. C.; Burkinshaw, R.; Beevers, S. J.; Coleman, R. E., The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response-exploratory evidence for direct anti-tumor activity in breast cancer. Presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 5101
51. Coleman, R.; Cook, R.; Hirsh, V.; Major, P.; Lipton, A., Zoledronic acid use in cancer patients: more than just supportive care? Cancer, 2011, 117(1), 11-23.
52. US National Institutes of Health, Study of Denosumab as Adjuvant Treatment for Women with High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE). http://www.clinicaltrials.gov/ct2/show/NCT01077154?term=D-CARE&rank=1. (Accessed November 22, 2010).
53. Meunier, P. J.; Vignot, E.; Garnero, P.; Confavreux, E.; Paris, E.; Liu-Leage, S.; Sarkar, S.; Liu, T.; Wong, M.; Draper, M. W., Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos. Int., 1999, 10(4), 330-336.
54. Visvanathan, K.; Chlebowski, R. T.; Hurley, P.; Col, N. F.; Ropka, M.; Collyar, D.; Morrow, M.; Runowicz, C.; Pritchard, K. I.; Hagerty, K.; Arun, B.; Garber, J.; Vogel, V. G.; Wade, J. L.; Brown, P.; Cuzick, J.; Kramer, B. S.; Lippman, S. M., American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol., 2009, 27(19), 3235-3258.
55. Ward, R. L.; Morgan, G.; Dalley, D.; Kelly, P. J., Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner., 1993, 22(2), 87-94.
56. Vassiliou, V.; Tselis, N.; Kardamakis, D., Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol., 2010, 186(7), 367-373.
57. Giusti, A.; Hamdy, N. A.; Papapoulos, S. E., Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone, 2010, 47(2), 169-180.